Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19501038 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TDP1CA2ALOX15ALOX12 | |
| SCHEMBL10338810 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TDP1CA2ALOX15ALOX12 | |
| SCHEMBL14477582 | 0.80 | ALDH1A1 (0.33) | ALDH1A1TDP1CA2 | |
| SCHEMBL16231258 | 0.77 | PRKCA (0.36) | ALDH1A1TDP1CA2 | |
| SCHEMBL19543003 | 0.77 | ALDH1A1 (0.35) | ALDH1A1TDP1CA2 | |
| SCHEMBL6722491 | 0.77 | — | — | |
| SCHEMBL9857573 | 0.76 | RNPEP (0.36) | ALDH1A1TDP1 | |
| SCHEMBL10835145 | 0.75 | CA2 (0.41) | ALDH1A1TDP1CA2 | |
| SCHEMBL11529375 | 0.75 | TDP1 (0.38) | ALDH1A1TDP1CA2 | |
| SCHEMBL109110 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20170304321-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | GRIN3B, GRIN2A, GRIN1 | ALDH1A1 1946/4885TDP1 4097/4885CA2 4792/4885 |
| US-20170304321-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | GRIN3B, GRIN2A, GRIN1 | ALDH1A1 1946/4885TDP1 4097/4885CA2 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.